First published · Last updated
A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: vaginal cancer sub cohort results
A journal article from XMLink presents results from the vaginal cancer subcohort of the phase II DART (SWOG S1609) trial of dual anti-CTLA-4 and anti-PD-1 therapy. The supplied excerpt contains no outcome data, patient counts, or location information.
Categories: science-and-space, public-health
Generated scores
Scores are based on the cited reporting and use a 1–10 scale. Read the methodology.
- Confidence
- 2/10
- Geographic reach
- 1/10
- Global importance
- 3/10
- Impact magnitude
- 3/10
- Positivity
- 5/10
- Urgency
- 2/10
Why it matters
It reports clinical trial findings relevant to treatment research in vaginal cancer.

